Upjohn lazaroid R&D
Executive Summary
FDA Commissioner Young told recent gathering in Washington D.C. he was "pleased" to hear that Upjohn might consider a Treatment IND for lazaroid R&D compounds. Senior VP Mark Novitch told analysts in December that Upjohn might use the Treatment IND procedure if the neuroprotective products showed promise during early clinical trials ("The Pink Sheet" Jan. 4, p. 10). Commenting on Novitch's remarks, Young said: "I was pleased to see the interest in . . . the Treatment IND . . . and the quoting of Mark Novitch and others talking about this as an opportunity. I think it is.".
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.